ARTHUR W. FRISCH, M.D.; ALVIN E. PRICE, M.D., F.A.C.P.; GORDON B. MYERS, M.D., F.A.C.P.
The purpose of the present study is to report the development of "sulfadiazine-tolerance" by a type VIII pneumococcus and the transmission of this strain to another patient by cross infection. The evidence to be presented in support of drug-fastness was obtained from the clinical course, laboratory findings, sputum examination, and growth studies of the pneumococci in media containing sulfonamides.
For the technic and detailed results of sputum examination, the reader is referred to previous publications. Serum therapy produced clumping and increased phagocytosis of pneumococci in the sputum, which was usually followed by a gradual decline in the number.3 The characteristic
FRISCH AW, PRICE AE, MYERS GB. TYPE VIII PNEUMOCOCCUS: DEVELOPMENT OF SULFADIAZINE RESISTANCE, TRANSMISSION BY CROSS INFECTION, AND PERSISTENCE IN CARRIERS(TYPE VIII PNEUMOCOCCUS: DEVELOPMENT OF SULFADIAZINE RESISTANCE, TRANSMISSION BY CROSS INFECTION, AND PERSISTENCE IN CARRIERS*). Ann Intern Med. 1943;18:271–278. doi: 10.7326/0003-4819-18-3-271
Download citation file:
Published: Ann Intern Med. 1943;18(3):271-278.
Infectious Disease, Streptococcal Infections.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use